Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II BNCT with borofalan (10B) for unresectable angiosarcoma
jRCT2031220410Phase 2Active, not recruiting
- Sponsor
- Stella Pharma
- Start
- Jan 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of borofalan in angiosarcoma, sponsored by Stella Pharma. Primary endpoint: Response rate. Started Jan 2023; status: active, not recruiting.
02
Drugs
borofalan
03
Conditions
angiosarcoma
Beyond the preview
Go deeper on jRCT2031220410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220410.